Havana, November 1 (RHC)-- The Roswell Park Institute, in the United States, announced the start of a new clinical study with the Cuban vaccine CIMAvax-EGF, developed by the Center for Molecular Immunology (CIM), to prevent lung cancer.

In a publication on the social network Twitter, Eduardo Martínez Díaz, president of the Group of the Biotechnological and Pharmaceutical Industries of Cuba (BioCubaFarma), referred to cancer as one of the leading causes of death in Cuba and the world.

He added that the evaluation of the ability to prevent lung cancer using the Cuban vaccine CIMAva-EGF, in clinical trials in Cuba and the United States, is a hope for humanity.

The new trial seeks to treat smoking patients at high risk of developing lung cancer and patients with early-stage cancer at risk of relapsing with the disease.

According to BioCubaFarma's Facebook profile, the Cuban drug CIMAvax-EGF, immunotherapy that manages to drastically reduce epidermal growth factor (EGF) levels in the blood, has demonstrated its efficacy in the treatment of advanced lung cancer.

Based on the results obtained in the two countries, researchers at the CIM and the Roswell Park Institute, located in New York State, are beginning to explore its use to prevent the development of lung cancer.

This would be the second ongoing clinical trial with CIMAvax-EGF at Roswell Park, where the safety of this drug has been demonstrated, and its combined use in several cancer indications is being explored, the social network publication noted.